Novavax Global Commercial Operations and COVID-19 Vaccine Update

Anti-rS IgG GMT (EC50) with 95% CI Robust IgG titers against Omicron sub-variants achieved with boosting using prototype strain vaccine Median age 51 - 53 years; Participants without evidence of infection 1,000,000 100,000 81,367 13,687 9,204 10,000 6,877 6,598 6,345 6,570 1,000 100 267,430 149,552 106,536 64,584 44,808 41,772 46,314 10 Prototype BA.1 BA.2 BA.5 BQ.1.1 BF.7 XBB.1 Prototype BA.1 BA.2 BA.5 BQ.1.1 BF.7 XBB.1 2-Dose Primary Series (n=18) novavax Assay conducted by Novavax Discovery Lab 8-Month Homologous Boost (n=15) © 2023 NOVAVAX. All rights reserved. 33 33 Approximates Phase 3 (VE=90%)

View entire presentation